Home > Our Doctors > Find a Doctor

Select Physicians to compare
Photo of David Harris

David T Harris , MD

Request an Appointment

Need help deciding?
Contact 1.866.CALL.MLH or
484.580.1000 for assistance.

Medical Group:

Physicians' Oncology Specialis

Primary Office:

Lankenau MOB South, Suite 417
100 East Lancaster Avenue
Wynnewood, PA  19096

Office Phone: 610.658.9690
Specialties Accepting New Patients
Hematology/Oncology
  Board Certified in 1976
Yes
Oncology
  Board Certified in 1977
No
Internal Medicine
  Board Certified in 1972
No
Age: 72     Gender: M

Medical School:
Harvard Medical School

Internship:
Philadelphia General Hospital

Residency:
Philadelphia General Hospital

Fellowships:

  • American Oncologic Hospital
  • McAfee Army Hospital

Primary Affiliation:  Lankenau Medical Center

* Members of the Main Line Health medical staff are affiliated with Bryn Mawr Hospital, Lankenau Medical Center, Paoli Hospital and Riddle Hospital.

Physicians' Oncology Specialis   (view other physicians at this practice)

Office Information

Location:
Lankenau MOB South, Suite 417
100 East Lancaster Avenue
Wynnewood, PA  19096

TEL: 610.658.9690 FAX: 610.658.9692
View Map | Get Directions

Access Information:
Public Transportation, Handicap Access

hours icon Hours: Weekdays
 
Physicians' Oncology Specialis
100 East Lancaster Avenue
Wynnewood, PA  19096

TEL: 610.658.9690 FAX: 610.658.9692

View Map | Get Directions

Access Information:
Public Transportation, Handicap Access

Hours:Weekdays



Titles

Academic Titles:
Clinical Professor of Medicine, Department of Medicine - Jefferson Medical College

Clinical/Dept Titles:

Senior Clinical Investigator
Lankenau Institute for Medical Research
Attending Physician

Recent Clinical Studies Published

Herlyn D, Somasundaram R, Zaloudik J, Li W, Jacob L, Harris D, Kieny M-P, Ricciardi R, Conczol E, Sears H, Mastrangelo M: Cloned Antigens and Idiotypes. Hybridoma 14:159-166, 1995.

Harris DT: Adjuvant Systemic Therapy for Breast Cancer. Semin Oncol 22: 553-570, 1995.

Harris DT, Matyas OR, Gomella LU, Talor E, Winship MD, Spitler LE, Mastrangelo, MJ. Immunologic Approaches to the Treatment of Prostate Cancer. Semin Oncol 26: 439-447, 1999.

Meidenbauer N, Harris DT, Spitler LE, Whiteside TL. Generation of PSA-Reactive Effector Cells After Vaccination with a PSA-Based Vaccine in Patients with Prostate Cancer. Prostate 43: 88-100, 2000.

Birebent B, Somasundaram R, Purev E, Akis N, Li W, Mitchell F, Hoey D, Bloom E, Mastrangelo M, Maguire H, Harris DT, Staib L, Braumuller H, Leeser C, Kuttner N, Berger H-G, Herlyn D. Anti-Idiotypic Antibody and Recombinant Antigen Vaccines in Colorectal Cancer Patients. Crit Rev Oncol Hematol 39: 107- 113, 2001.

Birebent B, Koido T, Mitchell F, Li W, Somasundaram R, Purev E, Hoey D, Mastrangelo M, Maguire H, Harris DT, Nair S, Cai D, Herlyn D. Anti-Idiotypic Antibody (Ab2) Vaccines: Coupling of Ab2 BR3E4 to KLH Increases Humoral and/or Cellular Immune Responses in Animals and Colorectal Cancer Patients. J Cancer Res Clin Oncol Suppl 2: R27-33, 2001.

Harris DT: Neuroendocrine Tumors. Revista Oncologia (in press).

Birebent B, Mitchell E, Li W, Somasundaram R, Purev E, Hoey D, Mastrangelo M, Maguire H, Harris D, Nair S, Cai D, Herlyn D. Monoclonal Anti-Idiotypic Antibody Mimicking the Gastrointestinal Carcinoma-Associated Epitope CO 17-1A Elicits Antigen-Specific Humoral and Cellular Immune Responses in Colorectal Cancer Patients. Clinical Cancer Research (in press).

Matyas GR, Harris DT, Alving CR, Mastrangelo M, Livingston P0, Talmadge JE, Muderhwa JM, Richards RL, Glenn G, Maida AE, Spitler LE. Induction of Antibodies to Prostate Specific Antigen by OncoVax-Pä, A Liposome-Based Vaccine for Therapy of Prostate Cancer. (in press).

Spitler LE, Harris DT, Matyas GR, Mastrangelo M, Livingston P0, Talmadge JE, Muderhwa JM, Reichert TE, Maida AE, Alving CR. Induction of Immune Responses to Prostate Specific Antigen (PSA) in Patients with Prostate Cancer by JBT 2001, a Vaccine for Therapy of Prostate Cancer. (in press).

Spitler LE, Smith DC, Harris DT, Corman J, Wilding G, Strum S, Meyers MF, Matyas GR, Alving CR, Mastrangelo M, Livingston P0, Maida AE, Brown BW, Small E. Phase II Trial of JBT 1001, a Vaccine for Therapy of Prostate Cancer, in Patients with Hormone Refractory Prostate Cancer. (in press).

Meidenbauer N, Gooding W, Spitler L, Harris D, Whiteside TL. Recovery of Chain Expression and Changes in IL-10 Production After PSA-Based Vaccines in Patients with Prostate Cancer. British J Cancer (in press).

Mullin JM, Valenzano MC, Steger HK, Harris DT, Mennel RG. The Effect of Vincristine on the Transepithelial Permeability of a Renal and Gastrointestinal Epithelium (in press).

Community/Team Clinical Affiliations

Member, Human Subjects Committee, The Wistar Institute.

Member, Cancer Committee, Genitourinary Cancer Subcommittee, Bioethics Committee Lankenau Hospital.

Current Memberships and Activities

Philadelphia County Medical Society
Pennsylvania Medical Society
Pennsylvania Society of Hematology/Oncology
Philadelphia Cancer Research Association

GENERAL

Specialties: Hematology/Oncology (Board Certified in 1976) - Accepting New Patients
Oncology (Board Certified in 1977) - Not Accepting New Patients
Internal Medicine (Board Certified in 1972) - Not Accepting New Patients
Age: 72     Gender: M

Medical School:
Harvard Medical School

Internship:
Philadelphia General Hospital

Residency:
Philadelphia General Hospital

Fellowships:

  • American Oncologic Hospital
  • McAfee Army Hospital

Primary Affiliation:  Lankenau Medical Center

* Members of the Main Line Health medical staff are affiliated with Bryn Mawr Hospital, Lankenau Medical Center, Paoli Hospital and Riddle Hospital.

Titles

Academic Titles:
Clinical Professor of Medicine, Department of Medicine - Jefferson Medical College

Clinical/Dept Titles:

Senior Clinical Investigator
Lankenau Institute for Medical Research
Attending Physician


PRACTICE

Practice Name:
Physicians' Oncology Specialis

appointment icon Location:

Lankenau MOB South, Suite 417
100 East Lancaster Avenue
Wynnewood, PA  19096
TEL: 610.658.9690 FAX: 610.658.9692
transportation icon Access Information:  Public Transportation,Handicap Access
hours icon Hours: Weekdays

PUBLICATIONS & CITATIONS

Recent Clinical Studies Published

Herlyn D, Somasundaram R, Zaloudik J, Li W, Jacob L, Harris D, Kieny M-P, Ricciardi R, Conczol E, Sears H, Mastrangelo M: Cloned Antigens and Idiotypes. Hybridoma 14:159-166, 1995.

Harris DT: Adjuvant Systemic Therapy for Breast Cancer. Semin Oncol 22: 553-570, 1995.

Harris DT, Matyas OR, Gomella LU, Talor E, Winship MD, Spitler LE, Mastrangelo, MJ. Immunologic Approaches to the Treatment of Prostate Cancer. Semin Oncol 26: 439-447, 1999.

Meidenbauer N, Harris DT, Spitler LE, Whiteside TL. Generation of PSA-Reactive Effector Cells After Vaccination with a PSA-Based Vaccine in Patients with Prostate Cancer. Prostate 43: 88-100, 2000.

Birebent B, Somasundaram R, Purev E, Akis N, Li W, Mitchell F, Hoey D, Bloom E, Mastrangelo M, Maguire H, Harris DT, Staib L, Braumuller H, Leeser C, Kuttner N, Berger H-G, Herlyn D. Anti-Idiotypic Antibody and Recombinant Antigen Vaccines in Colorectal Cancer Patients. Crit Rev Oncol Hematol 39: 107- 113, 2001.

Birebent B, Koido T, Mitchell F, Li W, Somasundaram R, Purev E, Hoey D, Mastrangelo M, Maguire H, Harris DT, Nair S, Cai D, Herlyn D. Anti-Idiotypic Antibody (Ab2) Vaccines: Coupling of Ab2 BR3E4 to KLH Increases Humoral and/or Cellular Immune Responses in Animals and Colorectal Cancer Patients. J Cancer Res Clin Oncol Suppl 2: R27-33, 2001.

Harris DT: Neuroendocrine Tumors. Revista Oncologia (in press).

Birebent B, Mitchell E, Li W, Somasundaram R, Purev E, Hoey D, Mastrangelo M, Maguire H, Harris D, Nair S, Cai D, Herlyn D. Monoclonal Anti-Idiotypic Antibody Mimicking the Gastrointestinal Carcinoma-Associated Epitope CO 17-1A Elicits Antigen-Specific Humoral and Cellular Immune Responses in Colorectal Cancer Patients. Clinical Cancer Research (in press).

Matyas GR, Harris DT, Alving CR, Mastrangelo M, Livingston P0, Talmadge JE, Muderhwa JM, Richards RL, Glenn G, Maida AE, Spitler LE. Induction of Antibodies to Prostate Specific Antigen by OncoVax-Pä, A Liposome-Based Vaccine for Therapy of Prostate Cancer. (in press).

Spitler LE, Harris DT, Matyas GR, Mastrangelo M, Livingston P0, Talmadge JE, Muderhwa JM, Reichert TE, Maida AE, Alving CR. Induction of Immune Responses to Prostate Specific Antigen (PSA) in Patients with Prostate Cancer by JBT 2001, a Vaccine for Therapy of Prostate Cancer. (in press).

Spitler LE, Smith DC, Harris DT, Corman J, Wilding G, Strum S, Meyers MF, Matyas GR, Alving CR, Mastrangelo M, Livingston P0, Maida AE, Brown BW, Small E. Phase II Trial of JBT 1001, a Vaccine for Therapy of Prostate Cancer, in Patients with Hormone Refractory Prostate Cancer. (in press).

Meidenbauer N, Gooding W, Spitler L, Harris D, Whiteside TL. Recovery of Chain Expression and Changes in IL-10 Production After PSA-Based Vaccines in Patients with Prostate Cancer. British J Cancer (in press).

Mullin JM, Valenzano MC, Steger HK, Harris DT, Mennel RG. The Effect of Vincristine on the Transepithelial Permeability of a Renal and Gastrointestinal Epithelium (in press).

Community/Team Clinical Affiliations

Member, Human Subjects Committee, The Wistar Institute.

Member, Cancer Committee, Genitourinary Cancer Subcommittee, Bioethics Committee Lankenau Hospital.

Current Memberships and Activities

Philadelphia County Medical Society
Pennsylvania Medical Society
Pennsylvania Society of Hematology/Oncology
Philadelphia Cancer Research Association

Membership on the medical staff of any of our hospitals does not constitute an employment or agency relationship.

Compare Physicians
  •  

Connect with MLH

New Appointments
1.866.CALL.MLH

 Well Ahead Newsletter


Connect With MLH

Copyright 2014 Main Line Health

Printed from: www.mainlinehealth.org/phy/page.asp?PageID=PHY000645

The information provided in this Web site is for informational purposes only. It is not a substitute for medical advice. All medical information presented should be discussed with your healthcare professional. See additional Terms of Use at www.mainlinehealth.org/terms. For more information, call 1.866.CALL.MLH.